Special Survey on PD Patients With Renal Dysfunction

Boehringer Ingelheim107 enrolled

Overview

The survey is conducted to collect safety and effectiveness information targeting patients who have both Parkinson's disease and renal dysfunction treated with Pramipexole in the daily clinical settings in Japan.

Study Type

OBSERVATIONAL

Enrollment

107

Conditions

Parkinson Disease

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: Patients with Parkinson's disease who have renal dysfunction with pretreatment creatinine clearance =\<70mL/min or whose renal dysfunction was determined by the physician Exclusion Criteria: None

Locations (98)

Outcomes

Primary Outcomes

Incidence of adverse events

Time frame: up to 12 weeks

Incidence of adverse drug reactions (ADRs

Time frame: up to 12 weeks

Incidence of serious adverse events (SAEs)

Time frame: up to 12 weeks

Secondary Outcomes

Modified Hoehn & Yahr rating scale

Time frame: change from baseline to week 12

Unified Parkinson's Disease Rating Scale (UPDRS) part III total score

Time frame: change from baseline to week 12

Physician's overall judgement by medical interview into 4 grades (5 categories)

Time frame: week 12

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.